EichorEICHOR
Study identifier: NCT06775860 Synced from ClinicalTrials.gov · August 07, 2026
● Study status: Recruiting

ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis

Condition: Atopic Dermatitis  ·  Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

PhasePhase 3
Planned participants552
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNoCheck eligibility criteria ↓
Where62 locations

Interested? Contact the study team ↓

Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.

About this study

A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis

This description comes directly from the study's public registry record.

Talk to the study team

Pengcheng Lei  ·  +86 18501252185  ·  pengcheng.lei@innocarepharma.com

There is no obligation to join — the study team can answer your questions about taking part.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Inclusion Criteria: 1. Male or female subjects between 18 and 75 years of age. 2. Clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for at least 1 year 3. Documented recent history of inadequate response to TCS or TCI, or for whom topical treatments are otherwise medically inadvisable. 4. Subjects must meet the following criteria for disease activity: * Eczema Area and Severity Index (EASI) score ≥ 16 ; * (Body Surface Area )BSA affected by AD ≥ 10% ; * (validated Investigator's Global Assessment-AD)vIGA-AD score ≥3 ; * Baseline weekly average of daily Worst Pruritus NRS ≥ 4. 5. Women of childbearing potential (WOCBP) and Men must agree 5\. Women of childbearing potential (WOCBP) and Men must agree to contraception. 6. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: 1. Lack of response or inadequate response to prior treatment with any JAK inhibitor for AD. 2. Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions. 3. Pregnant or breastfeeding females. 4. History of any clinically major diseases, with the exception of atopic dermatitis. 5. Consideration by the Investigator, for any reason, that the subject is an unsuitable candidate to receive ICP-332 or participate in this study.

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (62)

The First Affiliated Hospital of Anhui Medical UniversityHefei, Anhui, ChinaRecruiting
The Second Affiliated Hospital of Wannan Medical CollegeWuhu, Anhui, ChinaRecruiting
Capital Medical University Affiliated Beijing Chaoyang HospitalBeijing, Beijing Municipality, ChinaRecruiting
Peking University First HospitalBeijing, Beijing Municipality, ChinaRecruiting
Capital Medical University Affiliated Beijing Friendship HospitalBeijing, Beijing Municipality, ChinaRecruiting
Peking University Third HospitalBeijing, Beijing Municipality, ChinaRecruiting
Beijing Tongren Hospital, Capital Medical UniversityBeijing, Beijing Municipality, ChinaRecruiting
Beijing Tsinghua Changgung HospitalBeijing, Beijing Municipality, ChinaRecruiting
The First Affiliated Hospital of Chongqing Medical UniversityChongqing, Chongqing Municipality, ChinaRecruiting
Chongqing Traditional Chinese Medicine HospitalChongqing, Chongqing Municipality, ChinaRecruiting
The Affiliated Union Hospital of Fujian Medical UniversityFuzhou, Fujian, ChinaRecruiting
The First Affiliated Hospital of Fujian Medical UniversityFuzhou, Fujian, ChinaRecruiting

+ 50 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →